Drug
Dotarem
Dotarem: highest development phase Post-Market, developed by Guerbet. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Guerbet
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dotarem NCT01026389 | Post-Market | Peripheral Arterial Disease |
| Dotarem NCT01010932 | Phase 3 | Cerebral Arterial Diseases |
| Dotarem (gadoterate meglumine) NCT01211873 | Phase 3 | Diagnostic Self Evaluation |
Latest
No recent events.
Follow Dotarem on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.